ABSTRACT
Introduction: Globally, breast cancer is leading to cancer found among women. It is well known that cancer is an age-relateddisease and this holds true in breast cancer as well. Breast cancer is the most frequently diagnosed cancer in women, and itwas estimated that there will be 252,710 new cases of invasive breast cancer and 63,410 new cases of in situ breast cancersamong women in the United States in 2017.Purpose: The aim of the present study was to analyze the demographic spectrum of breast cancers in the Kashmir valley.Materials and Methods: This was an observational chart based study on breast cancer patients aged above 18 years of agewho were diagnosed with either invasive or in situ breast cancer at Government Medical College Hospital, Srinagar, Kashmir.The duration of the study was from June 2015 to December 2018. A retrospective study was conducted to find the informationregarding age, sex, clinical presentation, anatomical site, histopathological type, and stage of the disease.Results: A total of 151 patients with histopathologically confirmed breast cancers formed the study population. The majority of thepatients (46%) among females were <45 years of age and among males >45 years in age, with males and females constituting4% and 96% of patients in their respective groups. The upper outer quadrant was involved in 81 (54%) patients followed byupper inner 14% and central quadrant involvement in 25 (16%) patients. Among 151 patients, 42 women (28%) presented inStage IIA, 32 patients (21%) presented with Stage IIB disease, 19 patients (12%) in Stage IIIA, and 20 patients (13%) in StageIIIC; however, 17 patients (11%) presented with Stage IV disease. G2 was the most common histological grade. On the whole,liver was the most common presenting site for distant metastasis followed by lung and brain metastases.Conclusion: Early age, female sex, and residence within an endemic geographical region seem to be the prime determinantsaffecting breast cancer prevalence in a given population. A significant number of breast cancer patients in Kashmir presentwith early stage of disease and major clinical presentation were breast swelling. The majority of the cases reported in StagesII and III. Furthermore, there was significant number of patients presenting with metastasis, i.e., Stage IV.
ABSTRACT
Introduction: Ovarian cancer is the fourth most common cause of cancer deaths world wide and also the commonest causeof death among all gynecological cancers.Aims and Objectives: To study the clinico demographic profile and treatment patterns of Ovarian Ca in our population.Material and Methods: We conducted an analytical, non-randomized, cross-sectional study on the Clinico-Demographic profileof 731` patients with Ovarian Carcinoma who reported to our OPD between 2008 to 2015.Results: The mean age of patients was 45±1. 49 years. Most common age group of our patients at presentation was 46-60 years.Majority of patients 70% in our study were from rural area. The major clinical presentation of ovarian in our study was pelvic pain(36%) followed by abdominal distention (34%) and ascites (22%). Most common type of ovarian cancer was of surface epithelialtype (94%) followed by sex cord stromal tumor (3%) and germ cell tumour (1. 6%). Most of the cases 61% in the present studyhad presentation at advanced stages (stage III & IV) while as only 39% cases had presented at early stages (stage I & II).Majority of the patients having ovarian tumors underwent surgical staging with surgery in 88% cases. Chemotherapy was themost common adjuvant therapy in 38% patients who had malignant ovarian pathology and had advanced stage of diseases.while as 7 patients (1%) received radiotherapy for brain and bone mets.Conclusion: Majority of patients were from rural background with pelvic pain as most common presenting symptom Most ofour cases presented in late stages of disease. Greater awareness among our community is needed to reduce the morbidityand mortality associated with Ovarian Ca
ABSTRACT
Introduction: Lung cancer is the most common cancer worldwide and has a poor prognosis but integration of chemoradiationhas led to an increase in overall survival time and percentage of cured patients with acceptable toxicity.Purpose: The purpose of this study was to compare the efficacy of hyperfractionated (HFX) radiotherapy with conventionalradiotherapy and weekly concurrent paclitaxel in stage IIB/III non-small-cell lung cancer (NSCLC).Materials and Methods: A total of 60 patients were enrolled, of which 30 patients were given twice daily radiotherapy(1.2 Gy each) to a total of 72 Gy over 5–6 weeks and 30 patients were given single daily fraction (2 Gy) to a total of 66 Gy forthe same duration to achieve a comparable biological effective dose. Both groups received weekly 50 mg/m2 paclitaxel.Results: An overall response of 83.3% versus 56.6% with a partial response of 70% versus 53.3% and complete response(CR) of 13.3% versus 3% was seen in HFX radiotherapy versus conventional radiotherapy which was statistically significant(P = 0.04). 10 of 25 patients and 11 of 17 patients who achieved response in study and control groups, respectively, progressed.The median survival of patients in HFX radiotherapy arm was 18 months, compared to 9 months in conventional radiotherapyarm. The median time to local recurrence was 19 versus 11 months with local recurrence-free survival of 72% versus 66% at1 year follow-up. The 1 and 2 year survival rates were 76% and 40% in study arm and 50% and 26% in control arm (P - 0.005).Esophagitis (70% vs. 63.3%), skin reaction (70% vs. 63.3%), and radiation-induced pneumonitis (50% vs. 43.3%) were thecommon toxicities with no statistical significance between the two groups. Overall, there was mild chemotherapy-related toxicity.Conclusions: The combination of HFX radiation with weekly paclitaxel is effective treatment with a moderate degree of toxicityin stage IIB/III NSCLC. An average response to treatment and the use of lesser drugs have made us to consider this therapyin locally advanced NSCLC.